Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 5, 2026

Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider

View original at globenewswire.com
Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider Austin, United States, Feb…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Asia Pacific Human Vaccines Market is the fastest-growing globally, projected to register a CAGR of 5.89% during 2026–2033

    80% confidence

  • HPV vaccines are anticipated to record the fastest CAGR of 7.34% through 2026–2033

    80% confidence

  • COVID-19 vaccines dominated with a 31.25% share in 2025

    80% confidence

  • Research & Academic Institutes are forecasted to register the fastest CAGR of 7.21% during 2026–2033

    80% confidence

  • The Human Vaccines Market is driven by the rising awareness of preventive healthcare, expansion of national immunization programs, and rising cases of infectious and chronic diseases

    80% confidence

  • Online Pharmacy is expected to grow at the fastest CAGR of 6.78% during 2026–2033

    80% confidence

  • The market is challenged by high development costs, complex manufacturing processes, and strict regulatory requirements

    80% confidence

  • Geriatric vaccines are expected to grow at the fastest CAGR of 6.98% during 2026–2033

    80% confidence

  • Intradermal delivery is projected to expand at the fastest CAGR of 6.45% during the forecast period

    80% confidence

  • The U.S. Human Vaccines Market is expected to grow from USD 11.72 billion in 2025 to USD 15.17 billion by 2033, registering a CAGR of 3.30% during the forecast period

    80% confidence

  • Hospitals accounted for the largest share of 53.12% in 2025

    80% confidence

  • mRNA vaccines are expected to grow at the fastest CAGR of 7.12% during 2026–2033

    80% confidence

  • Hospital Pharmacy held the largest share of 45.87% in 2025

    80% confidence

  • Adult vaccines held the largest share of 39.61% in 2025

    80% confidence

  • Inactivated vaccines held the largest market share of 28.74% in 2025

    80% confidence

  • Government vaccination programs are an essential factor in the development of the market

    80% confidence

  • Intramuscular vaccines accounted for the highest market share of 46.32% in 2025

    80% confidence

  • North America dominated the Human Vaccines Market, accounting for a 34.56% market share in 2025

    80% confidence

  • The Human Vaccines Market size was valued at USD 44.26 billion in 2025 and is expected to reach USD 62.45 billion by 2033, growing at a CAGR of 4.43% during the forecast period of 2026-2033

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider — Source | Via News | Finance Via News